Sex disparities in receiving evidence-based medications in patients with CKD
Clicks: 1
ID: 317767
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #90 of 98 articles by views in nephrology dialysis transplantation
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background and Hypothesis Chronic kidney disease (CKD) is a growing global health burden. While studies have demonstrated sex disparities in CKD prevalence and outcomes, evidence on sex-based differences in therapeutic management remains limited. This analysis aims to assess sex disparities in the receipt of evidence-based medications in a global CKD cohort. Methods This study is a sub-study of the Global Kidney Patient Trials Network (GKPTN), a prospective, observational, international cohort of CKD patients. The exposure of this study is biological sex, and the main outcomes are the receipt of evidence-based medications for CKD, including renin-angiotensin system inhibitors (RASi), sodium glucose co-transporter 2 inhibitor (SGLT2i) and diuretics. Adjusted multivariable logistic models were conducted to examine associations between sex and proportion of receiving medications, as well as the interactions between sex and other key clinical characteristics (advanced age, high KDIGO prognosis risk, and comorbid condition). Results A total of 4192 participants were eligible, and 40.9% were female. Females had lower odds of receiving RASi (OR = 0.75, 95% CI 0.64–0.88; P < 0.001) and SGLT2i (OR = 0.79, 95% CI 0.64–0.98; P = 0.03) compared to males, after adjusting for age, region, systolic blood pressure (SBP), body mass index (BMI), presence of cardiovascular disease and diabetes, CKD aetiology and prognosis risk, with no significant difference in the receipt of diuretics. There were no significant interactions between sex and any other key clinical characteristics, indicating that the disparities in the receipt of RASi and SGLT2i remained consistent across high-risk subgroups. Conclusion Female patients with CKD are less likely to receive evidence-based medications than males, irrespective of established CKD risk factors. This difference highlights potential inequities in treatment globally which may result in outcome disparities.
| Reference Key |
openalex_W7165361132
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Rui Du, Hannah Wallace, Jeffrey T. Ha, Ben Talbot, Vlado Perkovic, Ian H. de Boer, M Jardine, Adeera Levin, José Luis Górriz, Hiddo J.L. Heerspink, Sradha Kotwal |
| Journal | nephrology dialysis transplantation |
| Year | 2026 |
| DOI |
10.1093/ndt/gfag135
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.